<table border="single" id="id_43989112-f626-4b36-9064-75b3ce202a7a" width="497.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="33.8%"></col>
<col width="34.4%"></col>
<col width="31.8%"></col>
<tbody>
<tr id="id_89b2ce65-b403-4d36-9746-3567b17a2f04">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">
<content stylecode="bold">Drug/Drug Class (Mechanism of Interaction by the Drug) </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Voriconazole Plasma Exposure (C<sub>max</sub> and AUC</content>τ<content stylecode="bold"> after 200 mg q12h) </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments </content>
</td>
</tr>
<tr id="id_50da73e3-7be7-4579-a1c9-ab6ad3d17668">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Rifampin*, and Rifabutin*</paragraph>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_99431210-ca5a-4d2f-a8df-13e795b3fd6e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Efavirenz** </paragraph>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h </td>
</tr>
<tr id="id_fa55a9ff-a028-4cdb-ae90-baa93e5f9c24">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>High dose Ritonavir (400 mg q12h)** (CYP450 Induction) </paragraph>Low dose Ritonavir (100 mg q12h)** (CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>Significantly Reduced </paragraph>Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>Coadministration of voriconazole and low dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </td>
</tr>
<tr id="id_76853672-9b96-4b95-9669-ca308474c099">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Carbamazepine </paragraph>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_0cf96256-d3a5-436f-9665-7b0024824605">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Long Acting Barbiturates </paragraph>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied<content stylecode="italics"> In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_1f3129ae-d1f9-4c90-b2cb-ce13812c12c0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Phenytoin* </paragraph>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg) </td>
</tr>
<tr id="id_311db9a5-277c-4457-86e6-950f1decc395">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>St. John’s Wort </paragraph>(CYP450 inducer; P-gp inducer) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_ccf0ec5c-86bf-4b52-ac94-19f423ffcda2">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Oral Contraceptives**</paragraph>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives </td>
</tr>
<tr id="id_22b5aa0e-6d4d-4439-b05f-977cdac4b126">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>Avoid concomitant administration of vorconazole and fluconazole Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole </paragraph>
</td>
</tr>
<tr id="id_99bb53d0-ca61-4ab4-910e-721bc6d6c65e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Other HIV Protease Inhibitors </paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure </paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir </paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors </td>
</tr>
<tr id="id_673c637d-515d-4f3e-8fbf-5cef3a505090">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Other NNRTIs***</paragraph>(CYP3A4 Inhibition or CYP450 Induction) </td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure) </paragraph>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole </paragraph>Careful assessment of voriconazole effectiveness </td>
</tr>
</tbody>
</table>